Ratings Daiichi Sankyo Company, Limited

Equities

Market Closed - Japan Exchange Other stock markets 07:30:00 18/07/2025 BST			5-day change	1st Jan Change
3,598.00 ^JPY	+0.28%		+12.09%	-17.33%

07-17	AstraZeneca, Daiichi Sankyo Win FDA Breakthrough Therapy Designation for Breast Cancer Drug	MT
07-17	AstraZeneca: ninth breakthrough designation for Enhertu

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
The company's MSCI ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

The group's high margin levels account for strong profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The group usually releases upbeat results with huge surprise rates.

In relation to the value of its tangible assets, the company's valuation appears relatively high.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Over the past four months, analysts' average price target has been revised downwards significantly.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Source: Surperformance

Source: MSCI

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Financial estimates revisions (Composite)	Capi.($)
	DAIICHI SANKYO COMPANY, LIMITED				45.1B
	ELI LILLY AND COMPANY				684B
	JOHNSON & JOHNSON				392B
	ABBVIE INC.				338B
	NOVO NORDISK A/S				292B
	ROCHE HOLDING AG				256B
	NOVARTIS AG				225B
	ASTRAZENECA PLC				214B
	MERCK & CO., INC.				205B
	AMGEN INC.				160B
	Average				281.15B
	Weighted average by Cap.